199 related articles for article (PubMed ID: 27473567)
1. PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatment.
Zhao L; So CW
Exp Hematol; 2016 Oct; 44(10):902-7. PubMed ID: 27473567
[TBL] [Abstract][Full Text] [Related]
2. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di RorĂ A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
3. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.
Esposito MT; Zhao L; Fung TK; Rane JK; Wilson A; Martin N; Gil J; Leung AY; Ashworth A; So CW
Nat Med; 2015 Dec; 21(12):1481-90. PubMed ID: 26594843
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitors in acute myeloid leukaemia therapy: How a synthetic lethality approach can be a valid therapeutic alternative.
Gafencu GA; Tomuleasa CI; Ghiaur G
Med Hypotheses; 2017 Jul; 104():30-34. PubMed ID: 28673584
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors: Synthetic lethality in the clinic.
Lord CJ; Ashworth A
Science; 2017 Mar; 355(6330):1152-1158. PubMed ID: 28302823
[TBL] [Abstract][Full Text] [Related]
7. PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
Fritz C; Portwood SM; Przespolewski A; Wang ES
Blood Rev; 2021 Jan; 45():100696. PubMed ID: 32482307
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
Ning J; Wakimoto H
Trends Cancer; 2020 Feb; 6(2):147-159. PubMed ID: 32061304
[TBL] [Abstract][Full Text] [Related]
10. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
Das S; Cardin D
Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
[TBL] [Abstract][Full Text] [Related]
11. Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.
Faraoni I; Giansanti M; Voso MT; Lo-Coco F; Graziani G
Biochem Pharmacol; 2019 Sep; 167():133-148. PubMed ID: 31028744
[TBL] [Abstract][Full Text] [Related]
12. Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD.
Dellomo AJ; Baer MR; Rassool FV
Cancer Lett; 2019 Jul; 454():171-178. PubMed ID: 30953707
[TBL] [Abstract][Full Text] [Related]
13. PARP Inhibitors in Prostate Cancer.
Ramakrishnan Geethakumari P; Schiewer MJ; Knudsen KE; Kelly WK
Curr Treat Options Oncol; 2017 Jun; 18(6):37. PubMed ID: 28540598
[TBL] [Abstract][Full Text] [Related]
14. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
15. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway.
Yang Q; Chen K; Zhang L; Feng L; Fu G; Jiang S; Bi S; Lin C; Zhou Y; Zhao H; Chen XL; Fu G; Xu B
Cancer Lett; 2019 Oct; 461():31-43. PubMed ID: 31301319
[TBL] [Abstract][Full Text] [Related]
16. PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
[TBL] [Abstract][Full Text] [Related]
17. Resurrection of PARP Inhibitors in Breast Cancer.
Lyons TG; Robson ME
J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
[TBL] [Abstract][Full Text] [Related]
18. Unifying targeted therapy for leukemia in the era of PARP inhibition.
Boila LD; Sengupta A
Exp Hematol; 2023 Aug; 124():1-14. PubMed ID: 37236341
[TBL] [Abstract][Full Text] [Related]
19. Anti-leukemic Activity of AIU2008 in FLT3-ITD-positive Acute Myeloid Leukemia.
Kim HJ; Ryu H; Choi HK; Song JY; Hwang SG; Ahn J
Anticancer Res; 2021 Feb; 41(2):731-737. PubMed ID: 33517277
[TBL] [Abstract][Full Text] [Related]
20. Evolving DNA repair synthetic lethality targets in cancer.
Kulkarni S; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Biosci Rep; 2022 Dec; 42(12):. PubMed ID: 36420962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]